Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07864870
Recruiting Observational

Sarcoma Care Adherence and Survival in Strasbourg

NCT07864870 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2025-11-27
Last updated
2026-10-08

Condition(s) studied

Soft Tissue Sarcoma (STS)

Study summary

This retrospective monocentric study evaluates adherence to international clinical practice guidelines for soft tissue sarcoma management in Strasbourg and its impact on overall survival. It also compares practices and outcomes between two periods (2010-2016 and 2017-2024).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient aged 18 years or older at first multidisciplinary tumor board presentation * Presented for multidisciplinary tumor board evaluation for soft tissue or visceral tumor * First presentation between 01/01/2017 and 31/12/2024 * Absence of opposition to reuse of medical data for research purposes Exclusion Criteria: * Presence of opposition to reuse of medical data for research purposes * Patient younger than 18 years at first presentation * Bone tumors, gastrointestinal stromal tumors (GIST), or Kaposi sarcoma * First presentation outside the study period * Management outside Alsace-Moselle * Duplicate records

Primary outcome measure(s)

  • Adherence to Good Clinical Practice and Overall Survival — From diagnosis up to end of follow-up (2017-2024)
    Evaluation of adherence to international guidelines using DELPHI criteria and assessment of overall survival defined as time from diagnosis to death from any cause

Trial sites (1)

FacilityCityRegionStatus
Service d'hématologie-oncologie pédiatrique - CHU de Strasbourg - France Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers Active, not recruiting
Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease Recruiting
Impact of Perioperative Organ Resuscitation of Brain-dead Deceased Organ Donor on Kidney Graft Function in the Recipient Recruiting
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine Recruiting
Study of the Care Pathway of Patients Admitted to the Palliative Care Unit of Strasbourg University Hospital From Their Home in 2025 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07864870 on ClinicalTrials.gov ↗ ← All trials in France